Division of Cardiovascular Health and Disease, Department of Internal Medicine, College of Medicine, 2514University of Cincinnati, Cincinnati, OH, USA.
J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):504-523. doi: 10.1177/10742484211046674. Epub 2021 Sep 17.
Cardiac reperfusion injury is a well-established outcome following treatment of acute myocardial infarction and other types of ischemic heart conditions. Numerous cardioprotection protocols and therapies have been pursued with success in pre-clinical models. Unfortunately, there has been lack of successful large-scale clinical translation, perhaps in part due to the multiple pathways that reperfusion can contribute to cell death. The search continues for new cardioprotection protocols based on what has been learned from past results. One class of cardioprotection protocols that remain under active investigation is that of controlled reperfusion. This class consists of those approaches that modify, in a controlled manner, the content of the reperfusate or the mechanical properties of the reperfusate (e.g., pressure and flow). This review article first provides a basic overview of the primary pathways to cell death that have the potential to be addressed by various forms of controlled reperfusion, including no-reflow phenomenon, ion imbalances (particularly calcium overload), and oxidative stress. Descriptions of various controlled reperfusion approaches are described, along with summaries of both mechanistic and outcome-oriented studies at the pre-clinical and clinical phases. This review will constrain itself to approaches that modify endogenously-occurring blood components. These approaches include ischemic postconditioning, gentle reperfusion, controlled hypoxic reperfusion, controlled hyperoxic reperfusion, controlled acidotic reperfusion, and controlled ionic reperfusion. This review concludes with a discussion of the limitations of past approaches and how they point to potential directions of investigation for the future.
心脏再灌注损伤是急性心肌梗死和其他类型缺血性心脏病治疗后的一种既定结果。许多心脏保护方案和疗法在临床前模型中取得了成功。不幸的是,由于再灌注可能导致细胞死亡的多种途径,成功的大规模临床转化仍然缺乏,部分原因可能是再灌注会导致细胞死亡的多种途径。人们继续寻找新的心脏保护方案,这些方案是基于从过去的结果中吸取的经验教训。一类仍在积极研究的心脏保护方案是控制性再灌注。这一类包括通过控制方式改变再灌注液的内容或再灌注液的机械特性(例如压力和流量)的方法。这篇综述文章首先概述了可能通过各种形式的控制性再灌注来解决的主要细胞死亡途径,包括无复流现象、离子失衡(特别是钙超载)和氧化应激。描述了各种控制性再灌注方法,并总结了临床前和临床阶段的机制和以结果为导向的研究。本综述将仅限于修饰内源性血液成分的方法。这些方法包括缺血后处理、温和再灌注、控制性低氧再灌注、控制性高氧再灌注、控制性酸中毒再灌注和控制性离子再灌注。本文最后讨论了过去方法的局限性,以及它们如何为未来的研究指明方向。